However, it is reported that treatment with PPARγ agonists, including pioglitazone, improved hepatic steatosis in patients with NAFLD [5,6,7], as well as in other animal models of NAFLD [16,17,18,19]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.